ImmuPharma plc (AIM:IMM)
London · Delayed Price · Currency is GBP · Price in GBX 4.300
+0.300 (7.50%)
May 6, 2026, 4:35 PM GMT
ImmuPharma Earnings Call Transcripts
Fiscal Year 2026
-
P140 remains the core focus, with licensing deals anticipated this year and strong scientific support. New funding, driven by shareholder interest, enables accelerated development of Kapiglucagon for Type I diabetes, targeting a $3 billion market with a rapid 18–24 month timeline.